（来源：南京晨报） 然而，进一步验证并确诊需要进行电子支气管镜检查，因为老人高龄家属担心风险，一度不愿接受检 查。徐春华及其团队多次与患者和家属沟通，充分解释病情与检查的必要性，从人文关怀出发减轻老人 顾虑。最终，患者和家属被打动，同意检查。 随着电子支气管镜深入气道——意想不到的一幕出现了：一枚"保健品瓶盖"稳稳嵌在右中间干支气管 内！这枚异物竟在老人气道中"潜伏"了一整年！造成反复咳嗽与肺不张。 数日后,患者进行了全麻下支气管异物取出术，在该院内镜中心侯志波主任和十二病区王伟主任医师的 联合操作下，这枚瓶盖被成功取出，在后续的抗感染治疗下，老人咳嗽症状明显好转，活动功能也逐步 恢复。 得益于接诊医师的临床敏感度以及"反复病史询问＋人文关怀"，终于揭开了困扰患者长达一年多的咳嗽 谜团。 转自：南京晨报 张奶奶已近90岁，一年多来反复遭受咳嗽、咳痰的困扰。在此期间，她曾到多家医院的呼吸科就诊，三 次胸部CT均显示右中肺不张，且多次接受抗感染治疗，但症状始终没有改善，也一直未能明确病因。 近日，张奶奶来到南京市胸科医院呼吸内科十二病区徐春华主任门诊就诊。徐春华反复、细致地追问病 史，关注到老人讲述中一处微弱却关 ...

Core Viewpoint - Zhongheng Group (600252.SH) announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received two medical device registration certificates from the Hainan Provincial Drug Administration for its products, enhancing its competitive edge in the medical device market [1] Group 1: Product Registration - The registered products include a medical electronic endoscope image processor (registration number: Qiong Xie Zhu Zheng 20252060115) and an electronic bronchoscope (registration number: Qiong Xie Zhu Zheng 20252060116) [1] - These products are developed by Laimei Medical Devices and are designed to directly observe patient images, aiding in clinical diagnosis and treatment [1] Group 2: Market Impact - The certification of these products will diversify the company's medical device offerings, meeting the varied demands of the market [1] - This development is expected to positively impact the company's future operations and enhance its overall competitiveness [1]

Core Viewpoint - Zhongheng Group announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received two medical device registration certificates from the Hainan Provincial Drug Administration for its medical electronic endoscope image processor and electronic bronchoscope, which are beneficial for clinical diagnosis and treatment of patients [1] Group 1 - The medical devices certified include an electronic endoscope image processor and an electronic bronchoscope [1] - The products developed by Laimei Medical Equipment allow direct observation of patient images, aiding in clinical judgment and treatment of conditions [1]

Core Insights - Zhongheng Group (600252.SH) announced that its subsidiary, Chongqing Laimei Pharmaceutical, received two medical device registration certificates from the Hainan Provincial Drug Administration for a medical electronic endoscope image processor and an electronic bronchoscope, both valid from November 17, 2025, to November 16, 2030 [1] Company Developments - The newly certified products allow direct observation of patient images, aiding in clinical diagnosis and treatment [1] - The certification will enhance the variety of medical device products offered by the company, meeting diverse market demands and improving overall competitiveness [1] - The positive impact on future operations is anticipated as a result of these developments [1]

Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

Core Viewpoint - Laimei Pharmaceutical (300006.SZ) announced that its subsidiary, Hainan Laimei Medical Equipment Co., Ltd., received two medical device registration certificates from the Hainan Provincial Drug Administration for a medical electronic endoscope image processor and an electronic bronchoscope [1] Group 1 - The company has received regulatory approval for two new medical devices, indicating progress in its product development and regulatory compliance [1] - The registered products include a medical electronic endoscope image processor and an electronic bronchoscope, which are significant for the medical imaging and respiratory care sectors [1]

Core Viewpoint - Laimei Pharmaceutical announced that its subsidiary, Hainan Laimei Medical Devices, received two medical device registration certificates from the Hainan Provincial Drug Administration for a medical electronic endoscope image processor and an electronic bronchoscope [1] Group 1 - The company has received regulatory approval for two new medical devices [1] - The products include a medical electronic endoscope image processor and an electronic bronchoscope [1]

Core Viewpoint - Laimei Pharmaceutical (300006.SZ) announced that its subsidiary, Hainan Laimei Medical Devices Co., Ltd., received two medical device registration certificates from the Hainan Provincial Drug Administration for its electronic endoscope image processor and electronic bronchoscope, enhancing its product offerings and competitive edge in the medical device market [1] Group 1 - The subsidiary received certification for two medical devices, which are the electronic endoscope image processor and electronic bronchoscope [1] - These products allow direct observation of patient images, aiding in clinical diagnosis and treatment [1] - The certification will diversify the company's medical device product range and meet market demand, positively impacting future operations [1]

Core Viewpoint - Laime Pharmaceutical (300006.SZ) announced that its subsidiary, Hainan Laime Medical Devices Co., Ltd., received two Medical Device Registration Certificates from the Hainan Provincial Drug Administration for its medical electronic endoscope image processor and electronic bronchoscope, enhancing its product offerings and competitive edge in the market [1] Group 1 - The medical electronic endoscope image processor and electronic bronchoscope are developed by Laime Medical Devices, allowing direct observation of patient images, which aids in clinical diagnosis and treatment [1] - The certification of these products will further enrich the company's medical device product range, meeting diverse market demands [1] - This development is expected to positively impact the company's future operations and overall competitiveness [1]